title: Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.
abstract: BACKGROUND
  To assess the relationship between androgen deprivation therapy (ADT) exposure and self-reported bone complications among men in a population-based cohort of prostate cancer survivors followed for 15 years after diagnosis.
  
  
  METHODS
  The Prostate Cancer Outcomes Study enrolled 3533 patients diagnosed with prostate cancer between 1994 and 1995. This analysis included participants with non-metastatic disease at the time of diagnosis who completed 15-year follow-up surveys to report development of fracture, and use of bone-related medications. The relationship between ADT duration and bone complications was assessed using multivariable logistic regression models.
  
  
  RESULTS
  Among 961 surviving men, 157 (16.3%) received prolonged ADT (>1 year), 120 (12.5%) received short-term ADT (⩽ 1 year) and 684 (71.2%) did not receive ADT. Men receiving prolonged ADT had higher odds of fracture (OR 2.5; 95% confidence interval (CI): 1.1-5.7), bone mineral density testing (OR 5.9; 95% CI: 3.0-12) and bone medication use (OR 4.3; 95% CI: 2.3-8.0) than untreated men. Men receiving short-term ADT reported rates of fracture similar to untreated men. Half of men treated with prolonged ADT reported bone medication use.
  
  
  CONCLUSIONS
  In this population-based cohort study with long-term follow-up, prolonged ADT use was associated with substantial risks of fracture, whereas short-term use was not. This information should be considered when weighing the advantages and disadvantages of ADT in men with prostate cancer.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Morgans
authors.affiliation: 1] Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA [2] Vanderbilt University Center for Quantitative Sciences and Department of Biostatistics, Nashville, TN, USA.
authors.forename: K-H
authors.initials: KH
authors.lastname: Fan
authors.affiliation: 1] Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA [2] Vanderbilt University Center for Quantitative Sciences and Department of Biostatistics, Nashville, TN, USA.
authors.forename: T
authors.initials: T
authors.lastname: Koyama
authors.affiliation: University of Connecticut Health Center, Farmington, CT, USA.
authors.forename: P C
authors.initials: PC
authors.lastname: Albertsen
authors.affiliation: Emory University, Atlanta, GA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Goodman
authors.affiliation: Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Hamilton
authors.affiliation: University of New Mexico, Albuquerque, NM, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Hoffman
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Stanford
authors.affiliation: University of Utah, Salt Lake City, UT, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Stroup
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: D F
authors.initials: DF
authors.lastname: Penson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001842:Bone and Bones / Q000187:drug effects*; D015331:Cohort Studies; D003625:Data Collection; D050723:Fractures, Bone / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018426:SEER Program; D017741:Survivors
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal